Analyst Price Targets — BNTC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 15, 2026 11:59 am | — | Wedbush | $17.00 | $11.73 | TheFly | Benitec Biopharma price target raised to $17 from $16 at Wedbush |
| July 28, 2026 10:51 am | — | Wedbush | $16.00 | $11.58 | TheFly | Benitec Biopharma initiated with an Outperform at Wedbush |
| May 12, 2026 12:14 pm | — | Evercore ISI | $25.00 | $12.01 | TheFly | Benitec Biopharma initiated with an Outperform at Evercore ISI |
| November 24, 2025 11:16 am | Raghuram Selvaraju | H.C. Wainwright | $32.00 | $13.26 | TheFly | Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright |
| November 4, 2025 5:30 pm | — | H.C. Wainwright | $35.00 | $15.69 | TheFly | Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright |
| November 4, 2025 10:42 am | — | JMP Securities | $22.00 | $15.86 | TheFly | Benitec Biopharma price target raised to $22 from $20 at Citizens JMP |
| September 16, 2025 12:08 pm | Andreas Argyrides | Oppenheimer | $29.00 | $13.66 | TheFly | Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer |
| October 14, 2024 8:24 am | Silvan Tuerkcan | JMP Securities | $18.00 | $10.86 | TheFly | Benitec Biopharma price target raised to $18 from $16 at JMP Securities |
| October 14, 2024 6:36 am | Silvan Tuerkcan | JMP Securities | $16.00 | $10.86 | TheFly | Benitec Biopharma price target lowered to $16 from $18 at JMP Securities |
| October 14, 2024 6:05 am | Mani Foroohar | Leerink Partners | $13.00 | $10.86 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC) |
Latest News for BNTC
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October Additional interim clinical study…
AWM Investment Company Inc. acquired a new position in Benitec Biopharma Limited (NASDAQ: BNTC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 187,977 shares of the biotechnology company's stock, valued at approximately $2,515,000. AWM Investment Company Inc. owned about 0.55% of
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BNTC.
U.S. House Trading
No House trades found for BNTC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.